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VI. Treatment Options 
IX. Conclusions 
II. Research Team I. Introduction 
IV. Comorbid Conditions 
The recent changes with respect to how professionals define and diagnose the 
condition of ADHD were the primary motivation for this study. It is important to 
evaluate the most up-to-date information related to ADHD across a range of 
scientific disciplines and to cast all the previous studies in light of the new 
definitions. Although we have only been exploring available scientific data for a 
about two months for this project, a notable challenge we have faced is the 
inconsistency of study parameters and the complexities involved in analyzing studies 
on human subjects to extract meaningful, clear conclusions. We hope to continue a 
detailed analysis of available original research studies in an effort to reveal clear 
understanding of the science behind ADHD and treatment options for so that non-
experts can make educated assessments related to the condition. 
III. ADHD in DSM-V: Definition and Diagnosis 
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There are numerous books about Attention-Deficit/Hyperactivity Disorder 
(ADHD) on the market. These books range from being very nontechnical, geared 
towards elementary educators and parents, to highly technical, geared towards 
medical and mental health professionals. To complicate matters further, the 
manner in which ADHD is defined and diagnosed has recently changed with the 
release of the DSM-V in 2013, which makes even relatively recent texts out-of-
date. This Creative Inquiry project involves research into the most recent data 
on the neurochemistry behind what causes ADHD and comorbid conditions, as 
well as the neurochemistry of how drugs used to treat these conditions work to 
affect patient mental health. The goal of this project is to write and publish a 
book that begins with simple descriptions of these processes and builds to 
more technical language, providing parents and teachers with the ability to 
become experts in ADHD without a preexisting background in science.  
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The manner in which ADHD is defined and diagnosed has recently undergone significant change 
with the release of the new Diagnosis and Statistics Manual V in 2013. One significant change is that 
the condition known as “ADD” is no longer a diagnosis that is made.  ADHD is now the recognized 
term for the condition. ADHD can present as one of three subconditions on the basis of which 
particular symptoms predominate in the patient: Predominantly inattentive, predominantly 
hyperactivity/impulsive, or combined type. From there the disorder can be classified as either mild, 
moderate, or severe.  
 
An essential feature of diagnosis is the persistence of inattention and/or hyperactivity-impulsivity 
that interferes with functioning of the patient or their development. Furthermore, symptoms and 
manifestations of the disorder must be present in multiple settings, such as home and school, work, 
etc.  
 
Inattention is viewed as lack of persistence, inability to concentrate on a set task, difficulty with 
sustaining focus, and being disorganized.  
 
Hyperactivity is viewed as excessive motor activity when it is deemed inappropriate, or excessive 
fidgeting, tapping or talkativeness.  
 
Impulsivity is known as actions taken or decisions made without forethought that has a high chance 
of causing harm to the individual. 
VII. Genetics VIII. Pregnancy and Risk Factors 
The most common statistics indicate that about 65% of ADHD patients have at least one comorbid 
condition. The graph below displays the frequencies of the more commonly observed conditions  in 
ADHD patients. 
 
Genetic factors and biochemical abnormalities play considerably large roles in the etiology of 
ADHD. Several molecular genetics studies have demonstrated that deficiencies in the 
serotonergic and dopaminergic systems (see box V) are associated with brain abnormalities 
that cause major symptoms of ADHD. Two dopamine candidate genes have been identified 
through numerous genetic studies and show a strong association with the neuropsychiatric 
disorder ADHD when expressed, specifically the dopamine transporter gene (DAT1) and the 
dopamine receptor gene (DRD4). Impaired dopamine transmission has a strong correlation 
with typical ADHD symptoms such as hyperactivity, inattention, and impulsivity. There is 
currently substantial evidence that links several genes coding for DRD4, DAT1, 5-HTT, DRD5, 
and HTR1B to the etiology of ADHD.  
 
Dopamine Genes 
• This DRD4 gene is expressed in the frontal lobe region of the brain and is involved in the 
dopaminergic system (see box V ) and affects functions like language processing, memory, 
and attention.  
 
• The association between a 48 base-pair repeat polymorphism of exon III of the DRD4 
gene and ADHD is the most consistent and replicated molecular genetic finding in ADHD.  
 
ADHD can be caused by a variety of genetic and environmental factors, including 
prenatal factors to which the fetus is exposed before birth. Recent studies have 
concluded that nicotine, alcohol, and mercury exposure in utero may lead to 
development of ADHD later in life. It is important to note that these studies have  
Comorbid conditions lead to an increase in 
the complexity of ADHD, impacting the 
symptoms, diagnosis, and prognosis of 
ADHD. In addition, comorbid conditions 
increase the difficulty of treatment 
selection. For the patient, comorbid 
conditions increase the morbidity and 
disease burden of ADHD and also may 
affect patient compliance, leading to 
further difficulties in treatment.  
 
Analyzing the true correlation/coincidence 
of ADHD and other conditions is 
complicated by the additional influence of 
socioeconomic standing, risk factors in 
pregnancy (see box VIII), etc. 
 
shown a correlation, but not necessarily a 
causative effect between these substances 
and the onset of ADHD. It is possible that 
these substances are part of larger 
environmental and genetic (See box VII) 
components and do not impair fetal 
development on their own. Either way, it is 
essential for mothers to be informed on these 
issues and how their actions can affect their 
child’s mental development. This appears to 
be an area requiring significant additional 
research. 
Dopamine plays a role in memory and 
reinforcement  (see image to the right) but in 
ADHD patients, Dopamine Transmission levels are 
found to be decreased, causing inattention and 
difficulty in memory formation.  
Serotonin is a key component in controlling 
impulsivity and the ADHD brain has a decreased 
number of serotonin receptors (see image to the 
right), leading to hyperactivity and impulsivity. 
Norepinephrine is also involved in cognition and 
behavior, but the receptors for norepinephrine are 
much less efficient in ADHD patients’ brains than 
healthy brains (see image to the left). This leads to 
poor neuron function, leading to impulsivity and 
inattention. 
There are both medicinal and non-medicinal treatment options for ADHD, with medicinal options 
being much more common and offering much more consistent results. 
 
FDA approved medications for ADHD are broken down into stimulants and non-stimulants: 
Stimulants: 
• Methylphenidate (Ritalin)- The most common psychoactive stimulant prescribed, it is believed to 
work by inhibiting the dopamine transporter (see box V, upper figure) in the presynaptic cell 
membrane, blocking its reuptake, causing an increase of dopamine in the synapse  
• Amphetamine (Adderall)- Believed to work through increasing levels of neurotransmitters, 
including dopamine and norepinephrine, in the synapse by causing the release of newly 
synthesized cytosolic dopamine from the nerve terminal  
Non-stimulants: 
• Atomoxetine (Strattera)- a specific presynaptic inhibitor of norepinephrine reuptake (see box V, 
middle figure), increasing the levels of the neurotransmitter in the synapse 
• α-2 Agonists (Kapvay and Intuniv)- inhibit the release of the norepinephrine neurotransmitter 
(see box V, middle figure), which decreases the body’s state of arousal 
Non-medicinal options: 
• Behavioral therapy, cognitive therapy, neurofeedback, modifying diet/nutrition, and increasing 
exercise  
